secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0001477932-23-001496
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx FY22 revenue $300k, cash $10.9M; Heska deal advances with $10M upfront
--------------------------------------------------------------------------------

- Revenue $0.3M, up 240% YoY; net cash used in operations $15.3M ($1.3M/month).
- Cash & equivalents $10.9M at Dec 31, 2022; raised ~$8.0M net in Feb 2023 offering.
- Heska agreement: $10M upfront received, up to $18M milestones; IDEXX launched Nu.Q Vet test.
- Nu.Q NETs CE marked; FDA Breakthrough Device application expected H1 2023.
- 34 patent families, 97 granted patents; capital market day set for May 11, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793223001496/0001477932-23-001496-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793223001496/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-23-001496

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer